Found: 9
Select item for more details and to access through your institution.
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359221146131
- By:
- Publication type:
- Article
Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221139678
- By:
- Publication type:
- Article
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919870360
- By:
- Publication type:
- Article
Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors—Navigating the Radiologic Potpourri.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1689, doi. 10.3390/cancers13071689
- By:
- Publication type:
- Article
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919870360
- By:
- Publication type:
- Article
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 22, p. 3152, doi. 10.1111/1759-7714.14667
- By:
- Publication type:
- Article
Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer.
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 1, p. 169, doi. 10.1002/ijc.33534
- By:
- Publication type:
- Article
Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
- Published in:
- Oncology, 2021, v. 99, n. 3, p. 192, doi. 10.1159/000512000
- By:
- Publication type:
- Article
Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank).
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.932212
- By:
- Publication type:
- Article